Drugs / Zalifrelimab
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05375903 | Jun 2022 → Jan 2026 | bladder carcinoma in situ | UroGen Pharma Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04943848 | Jan 2022 → Sep 2026 expected | diffuse midline glioma, H3 K27M-mutant | Ann & Robert H Lurie Children's Hospital of Chicago | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06782555 | Jan 2025 → Oct 2027 expected | head and neck squamous cell carcinoma, malignant pancreatic neoplasm, metastatic prostate carcinoma | ImmunoGenesis | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04827953 | Sep 2021 → Apr 2025 overdue | pancreatic ductal adenocarcinoma | Nelum Corp | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03495882 | Dec 2017 → Jul 2022 | cervical cancer | Agenus Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02694822 | Apr 2016 → Mar 2022 | high grade malignant neoplasm, refractory malignant neoplasm | Agenus Inc. | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT05033132 | Oct 2021 → Dec 2024 | cervical cancer | Agenus Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04607200 | Feb → Sep 2021 | angiosarcoma | Agenus Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04430036 | Oct 2020 → Oct 2021 | urinary bladder cancer | The University of Texas Health Science Center at San Antonio | Terminated | No outcome recorded |
| Phase 2 | NCT04028063 | Jan 2020 → Apr 2027 expected | soft tissue sarcoma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03894215 | Jun 2019 → Mar 2025 | cervical cancer | Agenus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03411473 | Oct 2017 → May 2018 | non-small cell lung carcinoma | Agenus Inc. | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05572970 | — | cancer | Agenus Inc. | Available | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zalifrelimab | “UGN-301 (zalifrelimab) administered intravesically as monotherapy and in combination with other agents in patients with recurrent NMIBC.” NCT05375903 ↗ |
| Known as | AGEN1884 | “Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)” NCT05572970 ↗ |
| Known as | UGN-301 | “UGN-301 (zalifrelimab) administered intravesically as monotherapy and in combination with other agents in patients with recurrent NMIBC.” NCT05375903 ↗ |
| Action | Inhibit | “An anti-CTLA-4 monoclonal antibody.” NCT02694822 ↗ |
| Modality | Monoclonal antibody | “An anti-CTLA-4 monoclonal antibody.” NCT02694822 ↗ |
| Route | Intravenous | “Participants received zalifrelimab intravenously.” NCT02694822 ↗ |
| Target | CTLA4 | “An anti-CTLA-4 monoclonal antibody.” NCT02694822 ↗ |